Lymphatic and blood vessels in basal and triple-negative breast cancers: Characteristics and prognostic significance

Modern Pathology

Volumn 24, Issue 6, 2011, Pages 774-785

  Mohammed, Rabab A A ^a,b   Ellis, Ian O ^b   Mahmmod, Ali M ^a   Hawkes, E Claire ^b   Green, Andrew R ^b   Rakha, Emad A ^c   Martin, Stewart G ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

basal phenotype; breast cancer; lymphatic; lymphovascular invasion; metastasis; triple negative

Indexed keywords

CD31 ANTIGEN; CD34 ANTIGEN; PODOPLANIN;

ARTICLE; BLOOD VESSEL; BREAST CANCER; CANCER INVASION; CAPILLARY DENSITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TRIPLE NEGATIVE BREAST CANCER;

BLOOD VESSELS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79957904691     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.4     Document Type: Article

References (50)

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
3. Rakha EA, El-Rehim DA, Paish C, et al. Basal pheno-type identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006;42: 3149-3156. (Pubitemid 44854512)
4. Rakha EA, Putti TC, Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506. (Pubitemid 43329336)
5. Luck AA, Evans AJ, Green AR, et al. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol) 2008;20:40-45.
6. Nielsen TO, Hsu FD, Jensen K, et al. Immunohisto-chemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374. (Pubitemid 39100473)
7. Rakha EA, El-Sayed ME, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007;50:434-438. (Pubitemid 46328193)
8. Dolle JM, Daling JR, White E, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18:1157-1166.
9. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009;20:1071-1082.
10. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 2009;250:638-647.
11. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008;123: 236-240. (Pubitemid 351705215)
12. Tan DS, Marchió C, Jones RL, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008;111:27-44. (Pubitemid 352009225)
13. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009;15:2302-2310.
14. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis\correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
15. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 1993;55:371-374. (Pubitemid 23300581)
16. Bevilacqua P, Barbareschi M, Verderio P, et al. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma\results of a multiparametric study. Breast Cancer Res Treat 1995;36:205-217.
17. Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941-2955. (Pubitemid 38581387)
18. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005;18:143-152. (Pubitemid 40128107)
19. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005;91:125-132. (Pubitemid 40684925)
20. Mohammed RA, Ellis IO, Elsheikh S, et al. Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Res Treat 2009;113:261-273.
21. Pinder SE, Ellis IO, Galea M, et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathol-ogy 1994;24:41-47. (Pubitemid 24223138)
22. Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg 1999;230:692-696. (Pubitemid 30191832)
23. Lee AH, Pinder SE, Macmillan RD, et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 2006;42:357-362. (Pubitemid 43132891)
24. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-3365. (Pubitemid 46606270)
25. Breiteneder-Geleff S, Soleiman A, Horvat R, et al. Podoplanin\a specific marker for lymphatic endo-thelium expressed in angiosarcoma. Verh Dtsch Ges Pathol 1999;83:270-275.
26. Birner P, Obermair A, Schindl M, et al. Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 2001;7:93-97. (Pubitemid 32110210)
27. Schoppmann SF, Birner P, Studer P, et al. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 2001;21: 2351-2355. (Pubitemid 33054395)
28. Evangelou E, Kyzas PA, Trikalinos TA. Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach. Mod Pathol 2005;18: 1490-1497. (Pubitemid 41509404)
29. Mohammed RA, Martin SG, Gill MS, et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 2007;31: 1825-1833. (Pubitemid 350175809)
30. Fox SB, Leek RD, Weekes MP, et al. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 1995;177:275-283.
31. Hansen S, Sørensen FB, Vach W, et al. Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathology 2004;44:428-436. (Pubitemid 38725671)
32. Zehnder JL, Hirai K, Shatsky M, et al. The cell adhesion molecule CD31 is phosphorylated after cell activation. Down-regulation of CD31 in activated T lymphocytes. J Biol Chem 1992;267:5243-5249.
33. Podgrabinska S, Braun P, Velasco P, et al. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci USA 2002;99:16069-16074. (Pubitemid 35462750)
34. Fiedler U, Christian S, Koidl S, et al. The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am J Pathol 2006;168:1045-1053. (Pubitemid 43327754)
35. Evans AJ, Rakha EA, Pinder SE, et al. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. J Med Screen 2007;14:210-214. (Pubitemid 350223786)
36. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26: 2568-2581.
37. Rakha EA, Reis-Filho JS, Ellis IO. Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology 2008;75:95-103. (Pubitemid 351820727)
38. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-578. (Pubitemid 29213215)
39. Arigami T, Natsugoe S, Uenosono Y, et al. Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer 2005;93:688-693. (Pubitemid 41486460)
40. Bono P, Wasenius VM, Heikkilä P, et al. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res 2004;10:7144-7149. (Pubitemid 39487698)
41. Kato T, Prevo R, Steers G, et al. A quantitative analysis of lymphatic vessels in human breast cancer, based on LYVE-1 immunoreactivity. Br J Cancer 2005;93: 1168-1174. (Pubitemid 41670702)
42. Ingeholm P, Pedersen L, Holck S. Quantification of microvessel density of breast carcinoma: an assessment of the inter-and intraobserver variation. Breast 1999;8:251-256.
43. Obermair A, Kurz C, Czerwenka K, et al. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer 1995;62:126-131.
44. Tsutsui S, Kume M, Era S. Prognostic value of microvessel density in invasive ductal carcinoma of the breast. Breast Cancer 2003;10:312-319.
45. Costello P, McCann A, Carney DN, et al. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 1995;26: 1181-1184.
46. Medri L, Nanni O, Volpi A, et al. Tumor microvessel density and prognosis in node-negative breast cancer. Int J Cancer 2000;89:74-80. (Pubitemid 30078753)
47. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
48. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-239.
49. Rodríguez-Pinilla SM, Sarrió D, Honrado E, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12:1533-1539.
50. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007;9:R4.